Nippon India Nifty Pharma ETF has outperformed many peers with a 10.1% return over the last three months. The fund tracks the Nifty Pharma Index, benefiting from recent sector momentum. However, investors should be aware of its 'Very High' risk rating and lack of diversification, as it is fully exposed to the pharmaceutical industry.
The Nippon India Nifty Pharma ETF has emerged as a top performer among index-based funds, recording a 10.1% return over the most recent three-month period. This performance highlights the recent momentum in the Indian pharmaceutical sector, which is the underlying market the fund tracks. As an exchange-traded fund, or ETF, it allows investors to buy and sell units on the stock exchange during trading hours, similar to how one would trade individual shares.
With an asset base of approximately ₹1,622 crore, the fund maintains a low expense ratio of 0.21%. In simple terms, the expense ratio is the cost of managing the fund. A lower ratio is generally favorable for investors, as it reduces the fees deducted from the fund's assets, potentially allowing more of the returns to remain with the investor over time.
While the recent gains are notable, investors must consider the specific risks of this product. The fund carries a 'Very High' risk rating, which is standard for sectoral funds. This is because the fund does not spread its investments across different industries like IT, banking, or manufacturing. Instead, it is entirely concentrated in the pharmaceutical sector. This concentration means that if the pharma industry faces negative developments—such as stricter regulatory oversight, drug pricing controls, or spikes in raw material costs—the fund's net asset value is likely to reflect those challenges directly.
Because the fund tracks the Nifty Pharma Index, its performance will generally move in line with the companies that make up that index. Investors monitoring this fund should pay attention to tracking error. This is a technical term for the small difference between the fund’s actual returns and the returns of the benchmark index it aims to mirror. Such differences can happen due to operational costs or the cash the fund must keep on hand.
Given its nature as a thematic fund, it lacks the broader market protection of diversified index funds. Consequently, many market participants view such ETFs as satellite investments to be used for tactical exposure to a specific sector, rather than as a core, long-term portfolio holding. Moving forward, the fund's performance will depend heavily on the earnings growth, new product approvals, and export market demand for the pharmaceutical companies within the index.